Abstract
<p>SFigure1: HER2+ breast cancer cells are sensitive to nirparib SFigure2: HER2+ breast cancer microtumors are sensitive to ABT-888 SFigure3: (A) ABT-888 reduces PAR levels in HER2+ xenograft models. (B) ABT-888 did not cause weight loss in mice SFigure4: Two different PARP-1 siRNAs decrease cell proliferation in HER2+ trastuzumab resistant breast cancer cells. SFigure5: Cell cycle distribution is not affected by PARPi in HER2+ trastuzumab resistant cell lines. SFigure6: IKK protein levels were decreased after treatment with Sigma-Aldrich''s PARP-1 siRNA. SFigure7: PARP-1 and IL-8 gene expression levels after PARP-1 knockdown or inhibition in HER2+ parental and trastuzumab resistant breast cancer cell lines. SFigure8: BRCA2 gene and protein expression levels in BT-474 trastuzumab resistant breast cancer cell lines after PARP-1 knockdown.</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
